{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T04:36:31Z","timestamp":1720154191964},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.2169\/internalmedicine.4260-19","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T22:04:04Z","timestamp":1586383444000},"page":"1639-1642","source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab"],"prefix":"10.2169","volume":"59","author":[{"given":"Takahiro","family":"Taki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reo","family":"Mitani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fukuyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Oshiro","sequence":"additional","affiliation":[{"name":"General Internal Medicine 3, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[{"name":"General Internal Medicine 4, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638-647, 2016.","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29: 250-255, 2018.","DOI":"10.1093\/annonc\/mdx642"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6: 1093-1099, 2018.","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5: 1310-1317, 2019.","DOI":"10.1001\/jamaoncol.2019.1022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mouri A, Kaira K, Yamaguchi O, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol 84: 873-880, 2019.","DOI":"10.1007\/s00280-019-03926-y"},{"key":"6","unstructured":"6. Sise ME, Seethapathy H, Reynolds KL. Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review. Oncologist 24: 735-742, 2019."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287-291, 2016.","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fadel F, El Karoui K KB. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211-212, 2009.","DOI":"10.1056\/NEJMc0904283"},{"key":"9","unstructured":"9. Gao B, Lin N, Wang S, et al. Minimal change disease associated with anti-PD1 immunotherapy: a case report. BMC Nephrol 19: 156, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. van den Brom RR, Abdulahad WH, Rutgers A, et al. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 55: 1143-1145, 2016.","DOI":"10.1093\/rheumatology\/kew063"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Izzedine H, Mathian A, Champiat S, et al. Renal toxicities associated with pembrolizumab. Clin Kidney J 12: 81-88, 2019.","DOI":"10.1093\/ckj\/sfy100"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36: 2872-2878, 2018.","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol 37: 1927-1934, 2019.","DOI":"10.1200\/JCO.19.00189"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355: 1428-1433, 2017.","DOI":"10.1126\/science.aaf1292"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Butte MJ, Pe\u00f1a-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 45: 3567-3572, 2008.","DOI":"10.1016\/j.molimm.2008.05.014"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/13\/59_4260-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T23:39:01Z","timestamp":1615160341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/13\/59_4260-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":15,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4260-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}